Astellas Pharma's proposed acquisition of OSI Pharmaceuticals: HSR waiting period expires

Download PDF Copy

Mar 19 2010

Astellas Pharma Inc. (TSE: 4503) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Astellas' proposed acquisition of OSI Pharmaceuticals Inc. (Nasdaq: OSIP) has expired.

On March 2, 2010, Astellas commenced a tender offer to acquire all of the outstanding shares of OSI for $52.00 per share in cash. The expiration of the HSR waiting period satisfies one of the conditions of the tender offer. The tender offer is not subject to any financing conditions or due diligence and only contains customary conditions to close.

Citigroup is acting as exclusive financial advisor to Astellas and Morrison & Foerster LLP is acting as legal counsel.

SOURCE Astellas Pharma Inc.

Posted in:

Comments (0)

Download PDF Copy

Suggested Reading

Targeting gut signaling protein may protect against alcohol-related liver damage

COPD care pathways improve hospital outcomes and standardize treatment

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

International commission calls for action against hepatocellular carcinoma

Hypothalamic neurons help maintain blood sugar during daily activities

University of Vienna team develops method to measure molecular charges

WHO expands global network of trusted medical product regulators

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.